share_log

Endexx Significantly Expands Distribution Network and Revenue Through Acquisition of Controlling Interest in Non-Nicotine Vape Producer, Hyla

Endexx Significantly Expands Distribution Network and Revenue Through Acquisition of Controlling Interest in Non-Nicotine Vape Producer, Hyla

Endexx通過收購非尼古丁Vape生產商Hyla的控股權大幅擴大分銷網絡和收入
GlobeNewswire ·  2022/09/08 05:36

Endexx Corporation

Endexx公司

Endexx Acquires Hyla
Endexx收購Hyla

Hyla Maintains International Distribution in 10 Countries, Including at Internationally Renowned UK Department Store, Harrods

Hyla在10個國家保持國際分銷,其中包括國際知名的英國百貨公司Harrods

CAVE CREEK, Ariz., Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx Corporation (OTC:EDXC), a provider of innovative, plant-based, and sustainable health and skincare products, today announces the acquisition of a controlling interest in Hyla US Holdco Limited, a producer and distributor of organic, plant-based, all-natural, zero-nicotine vape products.

亞利桑那州洞穴克里克,9月2022年8月8日(Global Newswire)--Via NewMediaWire-Endexx Corporation(場外交易市場代碼:EDXC)今天宣佈收購Hyla US Holdco Limited的控股權,Hyla US Holdco Limited是有機、植物、全天然、零尼古丁電子煙產品的生產商和分銷商。

The acquisition provides two key benefits to Endexx in the near term:

此次收購在短期內為Endexx帶來了兩個關鍵好處:

  • an expanded international distribution network in 10 countries - Dubai, Saudi Arabia, the United Kingdom, the Czech Republic, Slovakia, Germany, France, the Kingdom of Bahrain, Egypt, and Switzerland, which Endexx expects will provide further leverage for sales of its men's skin care line, Blesswell, as well as its CBD products designed for pain under its CBD Unlimited brand; and
  • a significant increase in Endexx's consolidated revenues, based on Hyla's distribution and sales to date of its non-nicotine, vegan vape products.
  • 在迪拜、沙特阿拉伯、英國、捷克共和國、斯洛伐克、德國、法國、巴林王國、埃及和瑞士等10個國家擴大國際分銷網絡,Endexx預計這將為其男士護膚品系列Bless well以及其CBD無限品牌下專為疼痛設計的CBD產品的銷售提供進一步的槓桿作用;以及
  • 基於Hyla迄今對其非尼古丁、素食Vape產品的分銷和銷售,Endexx的綜合收入大幅增長。

"This acquisition is an important opportunity for Endexx, as the ability to expand the distribution for our CBD and non-CBD Blesswell men's skin care products is a significant benefit. We have already achieved substantial success in the U.S. through our retail distribution in Walgreens, Target, and CVS and, as announced yesterday, Amazon. International distribution in Europe and the Middle East, with the potential of future distribution in Latin America and Asia, holds great promise," commented Endexx CEO Todd Davis.

Endexx首席執行官託德·戴維斯評論説:“此次收購對Endexx來説是一個重要的機會,因為能夠擴大我們CBD和非CBD百威男士護膚品的分銷是一個重大的好處。我們已經通過我們在Walgreens、Target和CVS以及昨天宣佈的亞馬遜的零售分銷在美國取得了巨大的成功。在歐洲和中東的國際分銷以及未來在拉丁美洲和亞洲的分銷潛力很大。”

Hyla currently markets its proprietary non-nicotine, guarana and L-dopa-based vape products in a wide variety of flavors. The Hyla device is the first non-nicotine vape product to be produced in this manner in the United States and provides an unprecedented 4,500 puffs per device. Introduced in October 2021, Hyla's initial inventory of 140,000 devices was sold out within the first month of availability. The Hyla vape products bear the Underwriters Laboratories global safety certification and is CE approved.

Hyla目前銷售其專有的非尼古丁、瓜拉納和基於左旋多巴的VAPE產品,口味多樣。Hyla設備是美國第一個以這種方式生產的非尼古丁電子煙產品,每個設備提供史無前例的4500口煙。Hyla於2021年10月推出,最初庫存的14萬台設備在上市的第一個月內就銷售一空。Hyla Vape產品通過了保險商實驗室的全球安全認證,並獲得了CE認證。

"Because Hyla's products do not contain any nicotine, and utilize the well-known plant, guarana, and other botanicals, we believe that Hyla's products may create a brand new vape market in the United States that avoids the issues associated with nicotine-based products," continued Mr. Davis. "We look forward to providing product and distribution updates in the near future."

“由於Hyla的產品不含任何尼古丁,並使用了著名的瓜拉納植物和其他植物,我們相信Hyla的產品可能會在美國創造一個全新的電子煙市場,避免與尼古丁產品相關的問題,”戴維斯繼續説。我們期待着在不久的將來提供產品和分銷更新。“

For additional information regarding the Hyla control acquisition, please refer to Endexx's Current Report on Form 8-K, which was filed with the United States Securities and Exchange Commission yesterday.

有關收購Hyla控制權的更多信息,請參閲Endexx昨天提交給美國證券交易委員會的8-K表格的最新報告。

About Endexx Corporation

關於Endexx公司

Endexx Corporation develops and distributes all natural, plant-derived topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health.

Endexx公司開發和分銷所有天然、植物衍生的局部護膚品。它的產品種類繁多,從香膏、面霜、乳液、黃油、面膜、磨砂膏和油,所有這些都以健康皮膚和美容健康為共同目標。這些產品背後的科學包括十年的現場臨牀研究和實驗室工作,以提供含有最佳吸收和支持皮膚健康的成分的功能配方。

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

《1995年私人證券訴訟改革法》下的安全港聲明

We caution that any forward-looking statements (as such term is defined in the U.S. Private Securities Litigation Reform Act of 1995) contained in this press release or made by us, our management, or our spokespeople involve risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. Accordingly, our future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Forward-looking statements include, without limitation, statements regarding our future operating results, the implementation and impact of our strategic plans, and our ability to meet environmental, social, and governance goals. Words such as "estimate," "commit," "target," "goal," "project," "plan," "believe," "seek," "strive," "expect," "anticipate," "intend," "potential" and any similar expressions may identify forward-looking statements. Risks associated with the following factors, among others, could affect our financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements:

我們提醒,本新聞稿中包含的或由我們、我們的管理層或我們的發言人做出的任何前瞻性聲明(根據1995年美國私人證券訴訟改革法中的定義)都涉及風險和不確定因素,並可能因各種因素而發生變化,其中許多因素是我們無法控制的。因此,我們未來的業績和財務結果可能與任何此類前瞻性陳述中明示或暗示的情況大不相同。前瞻性陳述包括但不限於關於我們未來的經營結果、我們戰略計劃的實施和影響以及我們實現環境、社會和治理目標的能力的陳述。諸如“估計”、“承諾”、“目標”、“目標”、“項目”、“計劃”、“相信”、“尋求”、“努力”、“期望”、“預期”、“打算”、“潛在”等詞彙以及任何類似的表述都可能識別前瞻性表述。與以下因素相關的風險可能會影響我們的財務業績,並導致實際結果與任何前瞻性陳述中明示或暗示的結果大不相同:

Except as may be required by law, we assume no obligation and do not intend to make publicly available any update or other revisions to any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release or to reflect the occurrence of future events, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized. More information on potential factors that could affect our results is included "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022.

除非法律另有要求,否則我們沒有義務也不打算公開提供對本新聞稿中包含的任何前瞻性陳述的任何更新或其他修訂,以反映本新聞稿發佈之日後存在的情況或未來事件的發生,即使經驗或未來事件明確表明,這些前瞻性陳述中明示或暗示的任何預期結果將無法實現。有關可能影響我們業績的潛在因素的更多信息,請參閲我們於2022年3月31日提交給美國證券交易委員會的Form 10-K年度報告中的“風險因素”。

For further information, please contact:
Endexx Corporation
Endexx@endexx.com
480-595-6900

如需更多信息,請聯繫:
Endexx公司
郵箱:endexx@endexx.com
480-595-6900

Investors:
Scott Arnold
CORE IR
scotta@coreir.com

投資者:
斯科特·阿諾德
核心紅外光譜
郵箱:Scotta@coreir.com

Media:
Jules Abraham
CORE IR
julesa@coreir.com
917-885-7378

媒體:
朱爾斯·亞伯拉罕
核心紅外光譜
郵箱:julesa@coreir.com
917-885-7378

Attachment

依附

  • Endexx Corporation
  • Endexx公司

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論